Sotalol Hydrochloride Tablet
Product Images NDC 55154-8179

5 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sotalol Hydrochloride (NDC 55154-8179). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Age Plotted On A Logarithmic Scale In Months (Age Factor)

Age Plotted On A Logarithmic Scale In Months (Age Factor)
A line graph depicting the relationship between age in months (x-axis) and age factor (y-axis). The age factor increases with age, reaching a value of 1.0 at 24 months and beyond, as noted by the annotation on the graph. The x-axis is logarithmically scaled from 0.1 to 50 months, and the y-axis ranges from 0.0 to 1.0.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure diagram of Sotalol Hydrochloride, showing its molecular components including sulfonamide, phenyl group, hydroxylated side chain, and hydrochloride salt.*
FDA Label Image

Figure 1: Study 1 – Time To First Ecg-documented Recurrence Of Symptomatic Afib/afl Since (Figure 1)

Figure 1: Study 1 – Time To First Ecg-documented Recurrence Of Symptomatic Afib/afl Since (Figure 1)
A graph showing the relationship between age in months (x-axis) and age factor (y-axis). The curve rises from approximately 0.18 at 0.1 months to 1.0 at about 24 months, indicating that the age factor gradually increases and reaches 1 for ages greater than 24 months.*
FDA Label Image

Figure 2: Study 2 – Time To First Ecg-documented Recurrence Of Symptomatic Afib/afl/death Since Randomization (Figure 2)

Figure 2: Study 2 – Time To First Ecg-documented Recurrence Of Symptomatic Afib/afl/death Since Randomization (Figure 2)
A Kaplan-Meier survival curve chart showing recurrence-free survival over 360 days for oral Sotalol at doses of 80 mg, 120 mg, and 160 mg compared to placebo. The chart includes p-values from a Log-Rank test for each dose versus placebo, illustrating differences in recurrence-free survival rates over time.*
FDA Label Image

80mg Bag Label (52434622 Ecc0 73e1 E063 6294a90a0859 00)

80mg Bag Label (52434622 Ecc0 73e1 E063 6294a90a0859 00)
Sotalol Hydrochloride Tablets USP 80 mg oral tablet label showing a 10 tablet package. The label includes storage instructions, dosage reference, warnings about child resistance, and distribution information by American Health Packaging and Cardinal Health. The NDC 55154-8179 is visible along with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.